Senseonics Raises $80 Million to Push Diabetes Tech Forward

Senseonics, a maker of implantable glucose monitors, has set the price for its upcoming stock sale. The company will offer eight million shares at five dollars each, aiming to bring in about eighty million dollars before fees. Investors can also receive pre‑funded warrants, which let them buy the same number of shares later at a slightly lower price. The deal includes an option for underwriters to buy another two million shares if needed. The sale is scheduled to close on May 4, 2026, provided all usual conditions are met. It is part of a larger registration filing that was approved last year, and the final documents will be posted on the SEC website. Anyone interested can request a copy from the banks handling the offering.Senseonics plans to use most of the money for its flagship product, the Eversense 365 sensor, and other new devices still in development. The company also wants to strengthen its working capital and support general operations. The announcement comes as the diabetes market grows, with more patients needing reliable long‑term monitoring. By raising capital, Senseonics hopes to expand its reach and improve the lives of people who rely on continuous glucose readings.